



## Clinical trial results:

### A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined with Intravesical BCG in Participants with BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer (CheckMate 9UT: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9UT)

#### Summary

EudraCT number	2017-003581-27
Trial protocol	FR ES GB NL IT
Global end of trial date	22 August 2022

#### Results information

Result version number	v1 (current)
This version publication date	19 May 2023
First version publication date	19 May 2023

#### Trial information

##### Trial identification

Sponsor protocol code	CA209-9UT
-----------------------	-----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03519256
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Bristol-Myers Squibb
Sponsor organisation address	Chaussee de la Hulpe 185, Brussels, Belgium, 1170
Public contact	EU Study Start-Up Unit, Bristol-Myers Squibb International Corporation, Clinical.Trials@bms.com
Scientific contact	Bristol-Myers Squibb Study Director, Bristol-Myers Squibb, Clinical.Trials@bms.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	17 November 2022
Is this the analysis of the primary completion data?	Yes
Primary completion date	22 August 2022
Global end of trial reached?	Yes
Global end of trial date	22 August 2022
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

To demonstrate that treatment with nivolumab, alone or in combination with BMS-986205, and with or without intravesical BCG, will be efficacious in participants with BCG-unresponsive NMIBC.  
As a result of Protocol Amendment 04, there are no formal hypotheses or efficacy objectives for this study. Only safety and immunogenicity assessments were conducted.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization Good Clinical Practice Guidelines. All the local regulatory requirements pertinent to safety of trial participants were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	02 August 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 4
Country: Number of subjects enrolled	Australia: 1
Country: Number of subjects enrolled	Brazil: 3
Country: Number of subjects enrolled	Canada: 8
Country: Number of subjects enrolled	Chile: 1
Country: Number of subjects enrolled	China: 3
Country: Number of subjects enrolled	Italy: 9
Country: Number of subjects enrolled	Netherlands: 5
Country: Number of subjects enrolled	Russian Federation: 3
Country: Number of subjects enrolled	Spain: 3
Country: Number of subjects enrolled	United Kingdom: 2
Country: Number of subjects enrolled	United States: 27
Worldwide total number of subjects	69
EEA total number of subjects	17

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	21
From 65 to 84 years	46
85 years and over	2

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

A safety lead-in was conducted in participants randomized to receive bacillus Calmette-Guerin (BCG) and nivolumab without BMS-986205 (Arm B), and Nivolumab Plus BMS-986205 Plus Intravesical BCG (Arm D) to determine safe-dose levels to be administered during the treatment phase.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Arm A: Nivolumab

Arm description:

Nivolumab 480 mg IV every 4 weeks (Q4W) for up to 52 weeks (12 months).

Arm type	Experimental
Investigational medicinal product name	Nivolumab (BMS-936558-01)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

480 mg as 30-minute IV every 4 weeks

<b>Arm title</b>	Arm B: Nivolumab Plus Intravesical BCG
------------------	--

Arm description:

Nivolumab 480 mg IV every 4 weeks (Q4W) for up to 52 weeks (12 months) and intravesical BCG (induction) weekly for 6 weeks followed by maintenance intravesical BCG weekly for 3 weeks at 3 months, 6 months and 12 months following the first intravesical dose.

Arm type	Experimental
Investigational medicinal product name	Bacillus Calmette-Guerin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Intravesical solution
Routes of administration	Intravesical use

Dosage and administration details:

Dose according to prescribing information for BCG strain and preparation. Taken once weekly for 6 weeks, followed by once weekly for 3 weeks at 3 months, 6 months, and 12 months after first BCG dose.

Investigational medicinal product name	Nivolumab (BMS-936558-01)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

480 mg as 30-minute IV every 4 weeks

<b>Arm title</b>	Arm C: Nivolumab Plus BMS-986205
------------------	----------------------------------

**Arm description:**

Nivolumab 480 mg IV every 4 weeks (Q4W) and 100 mg oral BMS-986205 daily for up to 52 weeks (12 months).

Arm type	Experimental
Investigational medicinal product name	Nivolumab (BMS-936558-01)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

480 mg as 30-minute IV every 4 weeks

Investigational medicinal product name	BMS-986205
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

100 mg orally per day for up to 52 weeks (12 months)

<b>Arm title</b>	Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG
------------------	--

**Arm description:**

Nivolumab 480 mg IV every 4 weeks (Q4W), 100 mg oral BMS-986205 daily for up to 52 weeks (12 months), and intravesical BCG (induction) weekly for 6 weeks followed by maintenance intravesical BCG weekly for 3 weeks at 3 months, 6 months, and 12 months following the first intravesical dose.

Arm type	Experimental
Investigational medicinal product name	Nivolumab (BMS-936558-01)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

480 mg as 30-minute IV every 4 weeks

Investigational medicinal product name	BMS-986205
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

100 mg orally per day for up to 52 weeks (12 months)

Investigational medicinal product name	Bacillus Calmette-Guerin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Intravesical solution
Routes of administration	Intravesical use

**Dosage and administration details:**

Dose according to prescribing information for BCG strain and preparation. Taken once weekly for 6 weeks, followed by once weekly for 3 weeks at 3 months, 6 months, and 12 months after first BCG dose.

Number of subjects in period 1	Arm A: Nivolumab	Arm B: Nivolumab Plus Intravesical BCG	Arm C: Nivolumab Plus BMS-986205
Started	16	26	17
Safety-Lead In Phase	0 <sup>[1]</sup>	10 <sup>[2]</sup>	0 <sup>[3]</sup>
Completed	6	15	2
Not completed	10	11	15
Disease recurrence	4	4	5
Disease progression	6	3	2
Study drug toxicity	-	2	5
Adverse event unrelated to study drug	-	1	1
Other reasons	-	-	2
Lost to follow-up	-	1	-
Participant request to discontinue study treatment	-	-	-

Number of subjects in period 1	Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG
Started	10
Safety-Lead In Phase	10
Completed	3
Not completed	7
Disease recurrence	2
Disease progression	1
Study drug toxicity	2
Adverse event unrelated to study drug	-
Other reasons	-
Lost to follow-up	-
Participant request to discontinue study treatment	2

Notes:

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Safety lead in was for Arms B and D only.

[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Safety lead in was for Arms B and D only.

[3] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Safety lead in was for Arms B and D only.

## Baseline characteristics

### Reporting groups

Reporting group title	Arm A: Nivolumab
Reporting group description: Nivolumab 480 mg IV every 4 weeks (Q4W) for up to 52 weeks (12 months).	
Reporting group title	Arm B: Nivolumab Plus Intravesical BCG
Reporting group description: Nivolumab 480 mg IV every 4 weeks (Q4W) for up to 52 weeks (12 months) and intravesical BCG (induction) weekly for 6 weeks followed by maintenance intravesical BCG weekly for 3 weeks at 3 months, 6 months and 12 months following the first intravesical dose.	
Reporting group title	Arm C: Nivolumab Plus BMS-986205
Reporting group description: Nivolumab 480 mg IV every 4 weeks (Q4W) and 100 mg oral BMS-986205 daily for up to 52 weeks (12 months).	
Reporting group title	Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG
Reporting group description: Nivolumab 480 mg IV every 4 weeks (Q4W), 100 mg oral BMS-986205 daily for up to 52 weeks (12 months), and intravesical BCG (induction) weekly for 6 weeks followed by maintenance intravesical BCG weekly for 3 weeks at 3 months, 6 months, and 12 months following the first intravesical dose.	

Reporting group values	Arm A: Nivolumab	Arm B: Nivolumab Plus Intravesical BCG	Arm C: Nivolumab Plus BMS-986205
Number of subjects	16	26	17
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	9	6	4
From 65-84 years	7	20	12
85 years and over	0	0	1
Age Continuous Units: Years			
arithmetic mean	61.8	69.0	69.1
standard deviation	± 11.1	± 9.4	± 12.3
Sex: Female, Male Units: Participants			
Female	2	4	5
Male	14	22	12
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	0	2	3
Not Hispanic or Latino	11	23	8
Unknown or Not Reported	5	1	6
Race/Ethnicity, Customized			

Units: Subjects			
White	13	26	17
Asian	3	0	0

<b>Reporting group values</b>	Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG	Total	
Number of subjects	10	69	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	2	21	
From 65-84 years	7	46	
85 years and over	1	2	
Age Continuous			
Units: Years			
arithmetic mean	69.9		
standard deviation	± 16.4	-	
Sex: Female, Male			
Units: Participants			
Female	1	12	
Male	9	57	
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	1	6	
Not Hispanic or Latino	9	51	
Unknown or Not Reported	0	12	
Race/Ethnicity, Customized			
Units: Subjects			
White	10	66	
Asian	0	3	



## End points

### End points reporting groups

Reporting group title	Arm A: Nivolumab
Reporting group description: Nivolumab 480 mg IV every 4 weeks (Q4W) for up to 52 weeks (12 months).	
Reporting group title	Arm B: Nivolumab Plus Intravesical BCG
Reporting group description: Nivolumab 480 mg IV every 4 weeks (Q4W) for up to 52 weeks (12 months) and intravesical BCG (induction) weekly for 6 weeks followed by maintenance intravesical BCG weekly for 3 weeks at 3 months, 6 months and 12 months following the first intravesical dose.	
Reporting group title	Arm C: Nivolumab Plus BMS-986205
Reporting group description: Nivolumab 480 mg IV every 4 weeks (Q4W) and 100 mg oral BMS-986205 daily for up to 52 weeks (12 months).	
Reporting group title	Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG
Reporting group description: Nivolumab 480 mg IV every 4 weeks (Q4W), 100 mg oral BMS-986205 daily for up to 52 weeks (12 months), and intravesical BCG (induction) weekly for 6 weeks followed by maintenance intravesical BCG weekly for 3 weeks at 3 months, 6 months, and 12 months following the first intravesical dose.	

### Primary: Number of Participants with Adverse Events (AEs)

End point title	Number of Participants with Adverse Events (AEs) <sup>[1]</sup>
End point description: An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs are reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.	
End point type	Primary
End point timeframe: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only summary statistics were planned for this endpoint.	

End point values	Arm A: Nivolumab	Arm B: Nivolumab Plus Intravesical BCG	Arm C: Nivolumab Plus BMS-986205	Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	26	17	10
Units: Participants	15	26	15	10

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants with Serious Adverse Events (SAEs)

End point title	Number of Participants with Serious Adverse Events (SAEs) <sup>[2]</sup>
-----------------	--

End point description:

Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose:

- Results in death
- Is life-threatening (an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe)
- Requires inpatient hospitalization or causes prolongation of existing hospitalization.

SAEs are reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

End point type	Primary
----------------	---------

End point timeframe:

From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics were planned for this endpoint.

End point values	Arm A: Nivolumab	Arm B: Nivolumab Plus Intravesical BCG	Arm C: Nivolumab Plus BMS-986205	Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	26	17	10
Units: Participants	2	2	5	3

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants with Adverse Events (AEs) Leading to Discontinuation of Study Treatment

End point title	Number of Participants with Adverse Events (AEs) Leading to Discontinuation of Study Treatment <sup>[3]</sup>
-----------------	---

End point description:

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs leading to discontinuation are reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

End point type	Primary
----------------	---------

End point timeframe:

From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics were planned for this endpoint.

End point values	Arm A: Nivolumab	Arm B: Nivolumab Plus Intravesical BCG	Arm C: Nivolumab Plus BMS-986205	Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	26	17	10
Units: Participants	1	4	8	7

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants Immune-Mediated Adverse Events (IMAEs)

End point title	Number of Participants Immune-Mediated Adverse Events (IMAEs) <sup>[4]</sup>
-----------------	--

End point description:

IMAEs are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity. IMAEs are reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

End point type	Primary
----------------	---------

End point timeframe:

From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics were planned for this endpoint.

End point values	Arm A: Nivolumab	Arm B: Nivolumab Plus Intravesical BCG	Arm C: Nivolumab Plus BMS-986205	Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	26	17	10
Units: Participants	1	10	6	5

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants Who Died

End point title	Number of Participants Who Died <sup>[5]</sup>
End point description: Number of participants who died.	
End point type	Primary
End point timeframe: From first dose to 100 days post last dose of study treatment (an average of 45 weeks up to approximately 74 weeks)	
Notes: [5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only summary statistics were planned for this endpoint.	

End point values	Arm A: Nivolumab	Arm B: Nivolumab Plus Intravesical BCG	Arm C: Nivolumab Plus BMS-986205	Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	26	17	10
Units: Participants	0	1	1	0

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Participants With Specific Liver Laboratory Abnormalities

End point title	Number of Participants With Specific Liver Laboratory Abnormalities <sup>[6]</sup>
End point description: On-treatment laboratory evaluations are evaluations taken after the day (and time, if collected and not missing) of first dose of study treatment. For participants who are off study treatment, evaluations were within a safety window of 30 days after the last dose of study treatment. ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase ULN = Upper Limit of Normal.	
End point type	Primary
End point timeframe: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)	
Notes: [6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only summary statistics were planned for this endpoint.	

End point values	Arm A: Nivolumab	Arm B: Nivolumab Plus Intravesical BCG	Arm C: Nivolumab Plus BMS-986205	Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	26	17	10
Units: Participants				
ALT OR AST > 3XULN	0	1	7	2
ALT OR AST > 5XULN	0	0	5	1

ALT OR AST > 10XULN	0	0	1	1
ALT OR AST > 20XULN	0	0	1	0
TOTAL BILIRUBIN > 2XULN	0	0	1	1
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>1.5XULN IN 1DAY	0	0	1	0
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>1.5XULN 30DAYS	0	0	1	0
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 1 DAY	0	0	1	0
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN 30DAYS	0	0	1	0
ALP>1.5XULN	0	2	1	0

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants With Specific Thyroid Laboratory Abnormalities

End point title	Number of Participants With Specific Thyroid Laboratory Abnormalities <sup>[7]</sup>
-----------------	--

End point description:

On-treatment laboratory evaluations are evaluations taken after the day (and time, if collected and not missing) of first dose of study treatment. For participants who are off study treatment, evaluations were within a safety window of 30 days after the last dose of study treatment.

TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal

End point type	Primary
----------------	---------

End point timeframe:

From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics were planned for this endpoint.

End point values	Arm A: Nivolumab	Arm B: Nivolumab Plus Intravesical BCG	Arm C: Nivolumab Plus BMS-986205	Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	26	17	10
Units: Participants				
TSH > ULN	5	5	2	1
TSH > ULN WITH TSH ≤ ULN AT BASELINE	4	5	1	1
TSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE <LLN	2	1	2	0
TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES ≥ LLN	2	3	1	0
TSH > ULN WITH FT3/FT4 TEST MISSING	2	3	0	1
TSH < LLN	2	3	3	1
TSH <LLN WITH TSH ≥ LLN AT BASELINE	2	3	3	1

TSH <LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE > ULN	2	1	1	1
TSH <LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN	1	3	0	0
TSH < LLN WITH FT3/FT4 TEST MISSING	0	0	2	0

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants with Changes from Baseline Laboratory Values

End point title	Number of Participants with Changes from Baseline Laboratory Values <sup>[8]</sup>
-----------------	--

End point description:

On-study laboratory parameters include hematology, chemistry, liver function, and renal function. On-study laboratory evaluations are evaluations taken after the day (and time, if collected and not missing) of first dose of study treatment. For participants who are off study treatment, evaluations were within a safety window of 30 days after the last dose of study treatment. On-study lab parameters are reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

End point type	Primary
----------------	---------

End point timeframe:

From baseline to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics were planned for this endpoint.

End point values	Arm A: Nivolumab	Arm B: Nivolumab Plus Intravesical BCG	Arm C: Nivolumab Plus BMS-986205	Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	26	17	10
Units: Participants				
Hemoglobin	1	7	5	6
Platelet Count	1	1	1	1
Leukocytes, Local Lab	0	0	4	0
Lymphocytes (Absolute)	0	0	3	0
Lymphocytes (Absolute), Local Lab	2	7	2	5
Absolute Neutrophil Count	0	1	1	0
Alkaline Phosphatase (ALP), Local Lab	0	2	2	1
Aspartate Aminotransferase (AST), Local Lab	3	5	12	3
Alanine Aminotransferase (ALT), Local Lab	4	10	13	7
Bilirubin Total, Local Lab	1	2	5	3
Creatinine, Local Lab	1	8	3	5
Hypernatremia	0	3	4	2
Hyponatremia	4	3	4	3
Hyperkalemia	0	3	2	3

Hypokalemia	2	2	1	1
Hypercalcemia	2	4	0	3
Hypocalcemia	0	1	2	2
Hypermagnesemia	3	1	2	0
Hypomagnesemia	1	3	1	3
Hyperglycemia	4	1	3	1
Hypoglycemia	0	1	1	0

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants with Adverse Events (AEs) by Anti-Drug- Antibody (ADA) Status

End point title	Number of Participants with Adverse Events (AEs) by Anti-Drug- Antibody (ADA) Status <sup>[9]</sup>
-----------------	---

End point description:

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.

An Anti-drug antibody (ADA) is defined as biologic drug-reactive antibody, including pre-existing host antibodies that are cross-reactive with the administered biologic drug.

An ADA-positive participant has at least one ADA positive-sample relative to baseline at any time after initiation of treatment

An ADA-negative participant doesn't not have an ADA-positive sample after the initiation of treatment.

End point type	Primary
----------------	---------

End point timeframe:

From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics were planned for this endpoint.

End point values	Arm A: Nivolumab	Arm B: Nivolumab Plus Intravesical BCG	Arm C: Nivolumab Plus BMS-986205	Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	11	22	13	9
Units: Participants				
Nivolumab ADA Positive	0	1	1	0
Nivolumab ADA Negative	11	21	11	9

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Participants with Serious Adverse Events (SAEs) by Anti-Drug-Antibody (ADA) Status

End point title	Number of Participants with Serious Adverse Events (SAEs) by Anti-Drug- Antibody (ADA) Status <sup>[10]</sup>
-----------------	---

End point description:

Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose:

- Results in death
- Is life-threatening (an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe)
- Requires inpatient hospitalization or causes prolongation of existing hospitalization.

An Anti-drug antibody (ADA) is defined as biologic drug-reactive antibody, including pre-existing host antibodies that are cross-reactive with the administered biologic drug.

An ADA-positive participant has at least one ADA positive-sample relative to baseline at any time after initiation of treatment

An ADA-negative participant doesn't not have an ADA-positive sample after the initiation of treatment.  
"99999" = Not Applicable/Not Available

End point type	Primary
----------------	---------

End point timeframe:

From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)

Notes:

[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics were planned for this endpoint.

End point values	Arm A: Nivolumab	Arm B: Nivolumab Plus Intravesical BCG	Arm C: Nivolumab Plus BMS-986205	Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	11	22	13	9
Units: Participants				
Nivolumab ADA Positive	99999	1	0	99999
Nivolumab ADA Negative	1	3	4	4

## Statistical analyses

No statistical analyses for this end point



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

SAEs and NSAEs were assessed from first dose to 100 days after last dose of study therapy (an average of 45 weeks up to approximately 74 weeks).

Adverse event reporting additional description:

SAEs and NSAEs represents all participants that received at least 1 dose of study medication.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	25.1
--------------------	------

### Reporting groups

Reporting group title	Arm A: Nivolumab
-----------------------	------------------

Reporting group description:

Nivolumab 480 mg IV every 4 weeks (Q4W) for up to 52 weeks (12 months).

Reporting group title	Arm B: Nivolumab Plus Intravesical BCG
-----------------------	--

Reporting group description:

Nivolumab 480 mg IV every 4 weeks (Q4W) for up to 52 weeks (12 months) and intravesical BCG (induction) weekly for 6 weeks followed by maintenance intravesical BCG weekly for 3 weeks at 3 months, 6 months and 12 months following the first intravesical dose.

Reporting group title	Arm C: Nivolumab Plus BMS-986205
-----------------------	----------------------------------

Reporting group description:

Nivolumab 480 mg IV every 4 weeks (Q4W) and 100 mg oral BMS-986205 daily for up to 52 weeks (12 months).

Reporting group title	Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG
-----------------------	--

Reporting group description:

Nivolumab 480 mg IV every 4 weeks (Q4W), 100 mg oral BMS-986205 daily for up to 52 weeks (12 months), and intravesical BCG (induction) weekly for 6 weeks followed by maintenance intravesical BCG weekly for 3 weeks at 3 months, 6 months, and 12 months following the first intravesical dose.

Serious adverse events	Arm A: Nivolumab	Arm B: Nivolumab Plus Intravesical BCG	Arm C: Nivolumab Plus BMS-986205
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 16 (25.00%)	7 / 26 (26.92%)	7 / 17 (41.18%)
number of deaths (all causes)	0	3	2
number of deaths resulting from adverse events	0	1	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Bladder cancer recurrent			
subjects affected / exposed	3 / 16 (18.75%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant neoplasm progression			

subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypotension			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Death			
subjects affected / exposed	0 / 16 (0.00%)	1 / 26 (3.85%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Disease recurrence			
subjects affected / exposed	0 / 16 (0.00%)	1 / 26 (3.85%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Pulmonary embolism			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Substance-induced psychotic disorder			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Confusional state			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			

subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Hip fracture			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural complication			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Ventricular arrhythmia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Nervous system disorders			
Carotid artery stenosis			
subjects affected / exposed	0 / 16 (0.00%)	1 / 26 (3.85%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 16 (0.00%)	1 / 26 (3.85%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis ulcerative			

subjects affected / exposed	0 / 16 (0.00%)	1 / 26 (3.85%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 16 (0.00%)	1 / 26 (3.85%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retroperitoneal haemorrhage			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Bile duct stone			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Urinary tract obstruction			
subjects affected / exposed	0 / 16 (0.00%)	1 / 26 (3.85%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 16 (0.00%)	1 / 26 (3.85%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Wound infection			

subjects affected / exposed	0 / 16 (0.00%)	1 / 26 (3.85%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural sepsis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG		
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 10 (50.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Bladder cancer recurrent			

subjects affected / exposed	1 / 10 (10.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Malignant neoplasm progression			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Hypotension			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Death			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Disease recurrence			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Pulmonary embolism			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Substance-induced psychotic disorder			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Confusional state			

subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Hip fracture			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Procedural complication			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Ventricular arrhythmia			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Carotid artery stenosis			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ischaemic stroke			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Diarrhoea			

subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Colitis ulcerative			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Colitis			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Retroperitoneal haemorrhage			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Bile duct stone			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Urinary tract obstruction			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haematuria			
subjects affected / exposed	2 / 10 (20.00%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		



Infections and infestations Wound infection subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 10 (0.00%) 0 / 0 0 / 0		
Sepsis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 10 (0.00%) 0 / 0 0 / 0		
Post procedural sepsis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 10 (0.00%) 0 / 0 0 / 0		
COVID-19 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 10 (0.00%) 0 / 0 0 / 0		
Metabolism and nutrition disorders Hyperglycaemia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 10 (10.00%) 0 / 1 0 / 0		
Hyponatraemia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 10 (10.00%) 0 / 1 0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Arm A: Nivolumab	Arm B: Nivolumab Plus Intravesical BCG	Arm C: Nivolumab Plus BMS-986205
Total subjects affected by non-serious adverse events			
subjects affected / exposed	15 / 16 (93.75%)	26 / 26 (100.00%)	15 / 17 (88.24%)
Vascular disorders			

Peripheral coldness subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 26 (0.00%) 0	0 / 17 (0.00%) 0
Flushing subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 26 (0.00%) 0	0 / 17 (0.00%) 0
Hypertension subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 26 (3.85%) 1	0 / 17 (0.00%) 0
Hypotension subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 26 (3.85%) 1	1 / 17 (5.88%) 1
Peripheral arterial occlusive disease subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 26 (0.00%) 0	0 / 17 (0.00%) 0
General disorders and administration site conditions			
Localised oedema subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 26 (0.00%) 0	0 / 17 (0.00%) 0
Influenza like illness subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 26 (3.85%) 1	0 / 17 (0.00%) 0
Gait disturbance subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 26 (0.00%) 0	0 / 17 (0.00%) 0
Fatigue subjects affected / exposed occurrences (all)	3 / 16 (18.75%) 3	9 / 26 (34.62%) 9	3 / 17 (17.65%) 4
Chills subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 26 (0.00%) 0	0 / 17 (0.00%) 0
Asthenia subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 2	1 / 26 (3.85%) 1	2 / 17 (11.76%) 2
Oedema peripheral			

subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	2 / 26 (7.69%) 2	1 / 17 (5.88%) 1
Thirst subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 26 (0.00%) 0	1 / 17 (5.88%) 1
Pyrexia subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 26 (0.00%) 0	0 / 17 (0.00%) 0
Pain subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 26 (0.00%) 0	0 / 17 (0.00%) 0
Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 26 (3.85%) 1	0 / 17 (0.00%) 0
Drug hypersensitivity subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 26 (0.00%) 0	1 / 17 (5.88%) 1
Reproductive system and breast disorders Testicular pain subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 26 (0.00%) 0	0 / 17 (0.00%) 0
Ejaculation disorder subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 26 (0.00%) 0	1 / 17 (5.88%) 1
Pelvic pain subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 26 (3.85%) 3	1 / 17 (5.88%) 1
Penile pain subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	2 / 26 (7.69%) 2	0 / 17 (0.00%) 0
Testicular mass subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 26 (0.00%) 0	0 / 17 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			

Cough			
subjects affected / exposed	0 / 16 (0.00%)	4 / 26 (15.38%)	1 / 17 (5.88%)
occurrences (all)	0	5	1
Dyspnoea			
subjects affected / exposed	0 / 16 (0.00%)	1 / 26 (3.85%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Epistaxis			
subjects affected / exposed	1 / 16 (6.25%)	1 / 26 (3.85%)	0 / 17 (0.00%)
occurrences (all)	1	3	0
Hiccups			
subjects affected / exposed	0 / 16 (0.00%)	1 / 26 (3.85%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Nasal congestion			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Pleural effusion			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 16 (0.00%)	1 / 26 (3.85%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Pulmonary oedema			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Pneumonitis			
subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Psychiatric disorders			
Alcohol withdrawal syndrome			
subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Anxiety			

subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 26 (0.00%) 0	1 / 17 (5.88%) 1
Confusional state subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 26 (0.00%) 0	0 / 17 (0.00%) 0
Insomnia subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 26 (0.00%) 0	2 / 17 (11.76%) 2
Persistent depressive disorder subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 26 (0.00%) 0	0 / 17 (0.00%) 0
Investigations			
Antinuclear antibody positive subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 26 (0.00%) 0	0 / 17 (0.00%) 0
Amylase increased subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 26 (0.00%) 0	1 / 17 (5.88%) 2
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	2 / 26 (7.69%) 6	4 / 17 (23.53%) 4
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 26 (3.85%) 3	5 / 17 (29.41%) 6
Carbohydrate antigen 19-9 increased subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 26 (0.00%) 0	0 / 17 (0.00%) 0
Blood urine present subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 26 (0.00%) 0	0 / 17 (0.00%) 0
Blood uric acid increased subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 26 (0.00%) 0	0 / 17 (0.00%) 0
Blood triglycerides increased			

subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Blood thyroid stimulating hormone increased			
subjects affected / exposed	2 / 16 (12.50%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	2	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	1	0	1
Blood methaemoglobin present			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Blood magnesium decreased			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Blood lactate dehydrogenase increased			
subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Blood creatinine increased			
subjects affected / exposed	0 / 16 (0.00%)	1 / 26 (3.85%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Blood bilirubin increased			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Blood thyroid stimulating hormone decreased			
subjects affected / exposed	1 / 16 (6.25%)	1 / 26 (3.85%)	0 / 17 (0.00%)
occurrences (all)	1	1	0
Heart rate irregular			
subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
International normalised ratio increased			

subjects affected / exposed	0 / 16 (0.00%)	1 / 26 (3.85%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Lipase increased			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	2
Neutrophil count increased			
subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Neutrophil percentage increased			
subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	2	0	0
PCO2 increased			
subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Transaminases increased			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Weight decreased			
subjects affected / exposed	1 / 16 (6.25%)	1 / 26 (3.85%)	0 / 17 (0.00%)
occurrences (all)	1	1	0
Injury, poisoning and procedural complications			
Vascular access site rash			
subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Stoma site hypergranulation			
subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Procedural pain			
subjects affected / exposed	2 / 16 (12.50%)	1 / 26 (3.85%)	1 / 17 (5.88%)
occurrences (all)	2	1	1
Postoperative respiratory failure			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Postoperative ileus			

subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Infusion related reaction			
subjects affected / exposed	0 / 16 (0.00%)	1 / 26 (3.85%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Hip fracture			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Fall			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Palpitations			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Ventricular extrasystoles			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Supraventricular tachycardia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Nervous system disorders			
Syncope			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Amnesia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	0 / 16 (0.00%)	3 / 26 (11.54%)	1 / 17 (5.88%)
occurrences (all)	0	4	1
Headache			
subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	1	0	1
Sinus headache			



subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 26 (0.00%) 0	0 / 17 (0.00%) 0
Blood and lymphatic system disorders			
Leukocytosis			
subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Anaemia			
subjects affected / exposed	3 / 16 (18.75%)	0 / 26 (0.00%)	2 / 17 (11.76%)
occurrences (all)	3	0	2
Thrombocytopenia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Neutropenia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Diplopia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Metamorphopsia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 16 (0.00%)	2 / 26 (7.69%)	0 / 17 (0.00%)
occurrences (all)	0	2	0
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	1 / 16 (6.25%)	1 / 26 (3.85%)	1 / 17 (5.88%)
occurrences (all)	1	1	1
Abdominal discomfort			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Constipation			

subjects affected / exposed	2 / 16 (12.50%)	2 / 26 (7.69%)	3 / 17 (17.65%)
occurrences (all)	2	2	3
Diarrhoea			
subjects affected / exposed	3 / 16 (18.75%)	4 / 26 (15.38%)	4 / 17 (23.53%)
occurrences (all)	3	4	4
Dry mouth			
subjects affected / exposed	0 / 16 (0.00%)	3 / 26 (11.54%)	0 / 17 (0.00%)
occurrences (all)	0	3	0
Ileus			
subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Flatulence			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Frequent bowel movements			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Haematochezia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Dyspepsia			
subjects affected / exposed	0 / 16 (0.00%)	1 / 26 (3.85%)	1 / 17 (5.88%)
occurrences (all)	0	1	1
Immune-mediated enterocolitis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	1 / 16 (6.25%)	1 / 26 (3.85%)	2 / 17 (11.76%)
occurrences (all)	1	1	2
Stomatitis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Proctitis			

subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 26 (0.00%) 0	1 / 17 (5.88%) 1
Pancreatitis subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 26 (0.00%) 0	0 / 17 (0.00%) 0
Nausea subjects affected / exposed occurrences (all)	2 / 16 (12.50%) 3	3 / 26 (11.54%) 3	2 / 17 (11.76%) 2
Inguinal hernia subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 26 (0.00%) 0	1 / 17 (5.88%) 1
Hepatobiliary disorders Hepatitis subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 26 (0.00%) 0	2 / 17 (11.76%) 2
Hepatic function abnormal subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 26 (0.00%) 0	0 / 17 (0.00%) 0
Drug-induced liver injury subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 26 (0.00%) 0	1 / 17 (5.88%) 1
Hyperbilirubinaemia subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 26 (0.00%) 0	1 / 17 (5.88%) 2
Skin and subcutaneous tissue disorders Hyperhidrosis subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 26 (0.00%) 0	0 / 17 (0.00%) 0
Dermatitis subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	2 / 26 (7.69%) 2	0 / 17 (0.00%) 0
Dermatitis acneiform subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 26 (0.00%) 0	1 / 17 (5.88%) 1
Dry skin			

subjects affected / exposed	0 / 16 (0.00%)	1 / 26 (3.85%)	1 / 17 (5.88%)
occurrences (all)	0	1	1
Intertrigo			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Lichenoid keratosis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Onychoclasia			
subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Pruritus			
subjects affected / exposed	3 / 16 (18.75%)	6 / 26 (23.08%)	3 / 17 (17.65%)
occurrences (all)	3	7	4
Rash			
subjects affected / exposed	1 / 16 (6.25%)	3 / 26 (11.54%)	1 / 17 (5.88%)
occurrences (all)	1	3	1
Rash maculo-papular			
subjects affected / exposed	0 / 16 (0.00%)	2 / 26 (7.69%)	1 / 17 (5.88%)
occurrences (all)	0	3	2
Skin ulcer			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 16 (0.00%)	1 / 26 (3.85%)	1 / 17 (5.88%)
occurrences (all)	0	1	1
Skin hyperpigmentation			
subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 16 (6.25%)	1 / 26 (3.85%)	0 / 17 (0.00%)
occurrences (all)	1	1	0
Pollakiuria			
subjects affected / exposed	2 / 16 (12.50%)	8 / 26 (30.77%)	1 / 17 (5.88%)
occurrences (all)	2	9	1

Dysuria			
subjects affected / exposed	0 / 16 (0.00%)	10 / 26 (38.46%)	1 / 17 (5.88%)
occurrences (all)	0	12	1
Haematuria			
subjects affected / exposed	4 / 16 (25.00%)	11 / 26 (42.31%)	4 / 17 (23.53%)
occurrences (all)	4	16	7
Hypertonic bladder			
subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	2	0	0
Leukocyturia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Micturition urgency			
subjects affected / exposed	0 / 16 (0.00%)	7 / 26 (26.92%)	0 / 17 (0.00%)
occurrences (all)	0	7	0
Nocturia			
subjects affected / exposed	0 / 16 (0.00%)	1 / 26 (3.85%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Bladder spasm			
subjects affected / exposed	0 / 16 (0.00%)	3 / 26 (11.54%)	0 / 17 (0.00%)
occurrences (all)	0	3	0
Proteinuria			
subjects affected / exposed	0 / 16 (0.00%)	1 / 26 (3.85%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Renal mass			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Renal pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Strangury			
subjects affected / exposed	0 / 16 (0.00%)	2 / 26 (7.69%)	0 / 17 (0.00%)
occurrences (all)	0	2	0
Urethral pain			
subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	1	0	1

Urinary incontinence subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	3 / 26 (11.54%) 6	1 / 17 (5.88%) 1
Urinary retention subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 26 (0.00%) 0	1 / 17 (5.88%) 2
Urinary tract obstruction subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 26 (0.00%) 0	0 / 17 (0.00%) 0
Urinary tract pain subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 26 (3.85%) 1	1 / 17 (5.88%) 1
Renal failure subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 3	0 / 26 (0.00%) 0	0 / 17 (0.00%) 0
Endocrine disorders Hypothyroidism subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	3 / 26 (11.54%) 5	2 / 17 (11.76%) 2
Hyperthyroidism subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 26 (0.00%) 0	1 / 17 (5.88%) 1
Glucocorticoid deficiency subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 26 (0.00%) 0	0 / 17 (0.00%) 0
Musculoskeletal and connective tissue disorders Flank pain subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 26 (0.00%) 0	1 / 17 (5.88%) 1
Arthralgia subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	6 / 26 (23.08%) 9	1 / 17 (5.88%) 1
Arthritis subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 26 (0.00%) 0	1 / 17 (5.88%) 1
Back pain			

subjects affected / exposed	0 / 16 (0.00%)	5 / 26 (19.23%)	2 / 17 (11.76%)
occurrences (all)	0	5	2
Joint range of motion decreased			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Joint swelling			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	0 / 16 (0.00%)	1 / 26 (3.85%)	1 / 17 (5.88%)
occurrences (all)	0	1	1
Myalgia			
subjects affected / exposed	1 / 16 (6.25%)	5 / 26 (19.23%)	0 / 17 (0.00%)
occurrences (all)	1	8	0
Myopathy			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Neck pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Tendon disorder			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Tenosynovitis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Pain in extremity			
subjects affected / exposed	1 / 16 (6.25%)	2 / 26 (7.69%)	1 / 17 (5.88%)
occurrences (all)	1	3	1
Infections and infestations			
Conjunctivitis			
subjects affected / exposed	1 / 16 (6.25%)	1 / 26 (3.85%)	0 / 17 (0.00%)
occurrences (all)	1	1	0
Candida infection			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1

Bacterial disease carrier			
subjects affected / exposed	0 / 16 (0.00%)	1 / 26 (3.85%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Cystitis			
subjects affected / exposed	0 / 16 (0.00%)	2 / 26 (7.69%)	0 / 17 (0.00%)
occurrences (all)	0	2	0
Sinusitis			
subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Tooth infection			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Device related infection			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Ear infection			
subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Groin infection			
subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Herpes zoster			
subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Infected skin ulcer			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Nail infection			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Orchitis			
subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Oropharyngeal candidiasis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0



Pneumonia			
subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Pneumonia klebsiella			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Pseudomonas infection			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Pyelonephritis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	2 / 17 (11.76%)
occurrences (all)	0	0	4
Upper respiratory tract infection			
subjects affected / exposed	1 / 16 (6.25%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Urinary tract infection			
subjects affected / exposed	1 / 16 (6.25%)	9 / 26 (34.62%)	2 / 17 (11.76%)
occurrences (all)	1	9	2
Wound infection			
subjects affected / exposed	1 / 16 (6.25%)	1 / 26 (3.85%)	0 / 17 (0.00%)
occurrences (all)	1	1	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 16 (0.00%)	1 / 26 (3.85%)	1 / 17 (5.88%)
occurrences (all)	0	1	1
Dehydration			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Diabetes mellitus			
subjects affected / exposed	1 / 16 (6.25%)	1 / 26 (3.85%)	0 / 17 (0.00%)
occurrences (all)	1	1	0
Hypercalcaemia			
subjects affected / exposed	2 / 16 (12.50%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	4	0	0
Hyperglycaemia			

subjects affected / exposed	5 / 16 (31.25%)	1 / 26 (3.85%)	2 / 17 (11.76%)
occurrences (all)	8	1	2
Hyperkalaemia			
subjects affected / exposed	0 / 16 (0.00%)	2 / 26 (7.69%)	0 / 17 (0.00%)
occurrences (all)	0	2	0
Hyperuricaemia			
subjects affected / exposed	1 / 16 (6.25%)	2 / 26 (7.69%)	0 / 17 (0.00%)
occurrences (all)	1	2	0
Hypocalcaemia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Hypokalaemia			
subjects affected / exposed	3 / 16 (18.75%)	2 / 26 (7.69%)	1 / 17 (5.88%)
occurrences (all)	4	2	1
Hypomagnesaemia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Hyponatraemia			
subjects affected / exposed	2 / 16 (12.50%)	0 / 26 (0.00%)	2 / 17 (11.76%)
occurrences (all)	3	0	2
Polydipsia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Steroid diabetes			
subjects affected / exposed	0 / 16 (0.00%)	0 / 26 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Hypophosphataemia			
subjects affected / exposed	1 / 16 (6.25%)	1 / 26 (3.85%)	1 / 17 (5.88%)
occurrences (all)	1	2	1

<b>Non-serious adverse events</b>	Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	10 / 10 (100.00%)		
Vascular disorders			

Peripheral coldness			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Flushing			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Hypertension			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Hypotension			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	2		
Peripheral arterial occlusive disease			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
General disorders and administration site conditions			
Localised oedema			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Influenza like illness			
subjects affected / exposed	5 / 10 (50.00%)		
occurrences (all)	5		
Gait disturbance			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Fatigue			
subjects affected / exposed	4 / 10 (40.00%)		
occurrences (all)	4		
Chills			
subjects affected / exposed	2 / 10 (20.00%)		
occurrences (all)	2		
Asthenia			
subjects affected / exposed	2 / 10 (20.00%)		
occurrences (all)	2		
Oedema peripheral			

subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Thirst			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Pyrexia			
subjects affected / exposed	2 / 10 (20.00%)		
occurrences (all)	3		
Pain			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	2		
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Drug hypersensitivity			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Reproductive system and breast disorders			
Testicular pain			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Ejaculation disorder			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Pelvic pain			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Penile pain			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Testicular mass			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Respiratory, thoracic and mediastinal disorders			

Cough			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Dyspnoea			
subjects affected / exposed	2 / 10 (20.00%)		
occurrences (all)	2		
Epistaxis			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Hiccups			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Nasal congestion			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Pleural effusion			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Productive cough			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Pulmonary oedema			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Rhinorrhoea			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Pneumonitis			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Psychiatric disorders			
Alcohol withdrawal syndrome			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Anxiety			

subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Confusional state			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Insomnia			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Persistent depressive disorder			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Investigations			
Antinuclear antibody positive			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Amylase increased			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Alanine aminotransferase increased			
subjects affected / exposed	4 / 10 (40.00%)		
occurrences (all)	6		
Aspartate aminotransferase increased			
subjects affected / exposed	4 / 10 (40.00%)		
occurrences (all)	5		
Carbohydrate antigen 19-9 increased			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Blood urine present			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Blood uric acid increased			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Blood triglycerides increased			

subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Blood thyroid stimulating hormone increased			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Blood methaemoglobin present			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Blood magnesium decreased			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Blood creatinine increased			
subjects affected / exposed	4 / 10 (40.00%)		
occurrences (all)	4		
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Blood bilirubin increased			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Blood thyroid stimulating hormone decreased			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Heart rate irregular			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
International normalised ratio increased			

subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	2		
Lipase increased			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Neutrophil count increased			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Neutrophil percentage increased			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
PCO2 increased			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Transaminases increased			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Weight decreased			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Injury, poisoning and procedural complications			
Vascular access site rash			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Stoma site hypergranulation			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Procedural pain			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Postoperative respiratory failure			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Postoperative ileus			



subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Infusion related reaction			
subjects affected / exposed	3 / 10 (30.00%)		
occurrences (all)	4		
Hip fracture			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Fall			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Cardiac disorders			
Palpitations			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Ventricular extrasystoles			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Supraventricular tachycardia			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Nervous system disorders			
Syncope			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Amnesia			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Dizziness			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Headache			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Sinus headache			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0		
Blood and lymphatic system disorders			
Leukocytosis			
subjects affected / exposed	2 / 10 (20.00%)		
occurrences (all)	3		
Anaemia			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Thrombocytopenia			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Neutropenia			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Eye disorders			
Diplopia			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	2		
Metamorphopsia			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Vision blurred			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Abdominal discomfort			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Abdominal pain			
subjects affected / exposed	2 / 10 (20.00%)		
occurrences (all)	2		
Constipation			

subjects affected / exposed	2 / 10 (20.00%)		
occurrences (all)	2		
Diarrhoea			
subjects affected / exposed	2 / 10 (20.00%)		
occurrences (all)	4		
Dry mouth			
subjects affected / exposed	2 / 10 (20.00%)		
occurrences (all)	2		
Ileus			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Flatulence			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Frequent bowel movements			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Haemorrhoids			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Haematochezia			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Dyspepsia			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Immune-mediated enterocolitis			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Vomiting			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Stomatitis			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Proctitis			

subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Pancreatitis			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Nausea			
subjects affected / exposed	3 / 10 (30.00%)		
occurrences (all)	4		
Inguinal hernia			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Hepatobiliary disorders			
Hepatitis			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Hepatic function abnormal			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Drug-induced liver injury			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Hyperbilirubinaemia			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Skin and subcutaneous tissue disorders			
Hyperhidrosis			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Dermatitis			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Dermatitis acneiform			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	3		
Dry skin			

subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Intertrigo			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Lichenoid keratosis			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Onychoclasia			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Pruritus			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Rash			
subjects affected / exposed	2 / 10 (20.00%)		
occurrences (all)	2		
Rash maculo-papular			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Skin ulcer			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	2		
Urticaria			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Skin hyperpigmentation			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	2 / 10 (20.00%)		
occurrences (all)	2		
Pollakiuria			
subjects affected / exposed	7 / 10 (70.00%)		
occurrences (all)	15		

Dysuria			
subjects affected / exposed	4 / 10 (40.00%)		
occurrences (all)	7		
Haematuria			
subjects affected / exposed	5 / 10 (50.00%)		
occurrences (all)	10		
Hypertonic bladder			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Leukocyturia			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	3		
Micturition urgency			
subjects affected / exposed	4 / 10 (40.00%)		
occurrences (all)	10		
Nocturia			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Bladder spasm			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Proteinuria			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	2		
Renal mass			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Renal pain			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Strangury			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Urethral pain			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		

Urinary incontinence subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 2		
Urinary retention subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0		
Urinary tract obstruction subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0		
Urinary tract pain subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 3		
Renal failure subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0		
Endocrine disorders Hypothyroidism subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0		
Hyperthyroidism subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1		
Glucocorticoid deficiency subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1		
Musculoskeletal and connective tissue disorders Flank pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0		
Arthralgia subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 2		
Arthritis subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1		
Back pain			

subjects affected / exposed	3 / 10 (30.00%)		
occurrences (all)	6		
Joint range of motion decreased			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Joint swelling			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Muscular weakness			
subjects affected / exposed	2 / 10 (20.00%)		
occurrences (all)	3		
Myalgia			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Myopathy			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Neck pain			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	2		
Tendon disorder			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Tenosynovitis			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Pain in extremity			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Infections and infestations			
Conjunctivitis			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Candida infection			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		



Bacterial disease carrier			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Cystitis			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Sinusitis			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Tooth infection			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Device related infection			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Ear infection			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Groin infection			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Herpes zoster			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Infected skin ulcer			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Nail infection			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Orchitis			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Oropharyngeal candidiasis			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	2		

Pneumonia			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Pneumonia klebsiella			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Pseudomonas infection			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Pyelonephritis			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Upper respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Urinary tract infection			
subjects affected / exposed	3 / 10 (30.00%)		
occurrences (all)	4		
Wound infection			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Dehydration			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Diabetes mellitus			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Hypercalcaemia			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Hyperglycaemia			

subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Hyperkalaemia			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Hyperuricaemia			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Hypocalcaemia			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Hypokalaemia			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Hypomagnesaemia			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Hyponatraemia			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Polydipsia			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Steroid diabetes			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		
Hypophosphataemia			
subjects affected / exposed	0 / 10 (0.00%)		
occurrences (all)	0		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
10 May 2019	Increased the window for screening procedures, decreased the number of required slides for biomarker analysis from 20 to 15, made random bladder biopsies at screening optional, allowed for urine cytology to be tested on a voided specimen, and increased the window for repeat TURBT for participants with stage T1 disease from 4 to 8 weeks to be consistent with professional society guidelines.
01 November 2019	Revised study design to pause enrollment into Arm D once the safety lead-in was completed. Introduced modified randomization to account for BCG availability. Removed eligibility for non-CIS participants. Deleted the endpoint of event free survival (EFS) in non-CIS participants.
22 September 2021	Details of closure of the study, with provision for participants currently on treatment to continue. Removal of pharmacokinetic (except for immunogenicity), biomarker, healthcare resource utilization, and patient-reported outcome (PRO) assessments. Details of closure of the study, with provision for participants currently on treatment to continue. Removal of pharmacokinetic (except for immunogenicity), biomarker, healthcare resource utilization, and patient-reported outcome (PRO) assessments. Removal of study-related efficacy assessment and Pathology Review Committee. Sites should continue efficacy assessment as per the local standard of care. Removal of study-related efficacy assessment and Pathology Review Committee. Sites should continue efficacy assessment as per the local standard of care.

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

As of early April 2021, study enrollment was significantly behind (number enrolled 142; target 480). Since the study would be unable to meet the scientific objectives within a projected timeline, it was decided in May 2021 to close the study.

Notes: